Program
emfizatamab
Its studies are mostly in Lymphoma, Non-Hodgkin · Lupus Erythematosus, Systemic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Extranodal NK-T-Cell · Arthritis, Rheumatoid, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 77 open or running | phase 2since Dec 15, 2021 | Oct 8, 2020 | Dec 2026phase 2 · NCT05623982 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 8, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04606433 · 47 enrolled · China
- Dec 15, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05192486 · 12 enrolled · China
- Jul 31, 2022Phase 2 study in Primary Central Nervous System LymphomaNCT05485753 · 7 enrolled · China
- Aug 25, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05623982 · 40 planned · China
- Nov 8, 2022Phase 2 study in Lymphoma, Extranodal NK-T-CellNCT05627856 · 4 enrolled · China
- Feb 26, 20252 phase 1 studiesNCT06857227, NCT06857214
Ahead
- Dec 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05623982
- Dec 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT06857227
- Dec 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06857214
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06857227Arthritis, Rheumatoid · China | 1 | Recruiting | Dec 2027 | 54 |
| NCT06857214Lupus Erythematosus, Systemic · China | 1 | Recruiting | Dec 2027 | 84 |
| NCT05627856Lymphoma, Extranodal NK-T-Cell · China | 2 | Active, not recruiting | Dec 2025 | 4 |
| NCT05623982Lymphoma, Non-Hodgkin · China | 2 | Recruiting | Dec 2026 | 40 |
| NCT05485753Primary Central Nervous System Lymphoma · China | 2 | Active, not recruiting | Dec 2025 | 7 |
| NCT05192486Lymphoma, Large B-Cell, Diffuse · China | 2 | Active, not recruiting | Dec 2025 | 12 |
| NCT04606433Lymphoma, Non-Hodgkin · China | 1 | Active, not recruiting | Dec 2025 | 47 |
How it is read
Names in the registry
- “GNC-038”, 7 entries
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 2 studies
- Lupus Erythematosus, Systemic, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lymphoma, Extranodal NK-T-Cell, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.